表紙
市場調查報告書

氣喘治療藥的全球市場 - 規模,佔有率,預測,及機會分析

Asthma Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

出版商 Coherent Market Insights 商品編碼 883788
出版日期 內容資訊 英文 157 Pages
商品交期: 2-3個工作天內
價格
Back to Top
氣喘治療藥的全球市場 - 規模,佔有率,預測,及機會分析 Asthma Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日期: 2019年06月12日內容資訊: 英文 157 Pages
簡介

這份報告提供全球氣喘治療藥市場的相關調查,提供市場機會和成長及阻礙因素,藥物類別·給藥途徑·流通管道·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 研究的目的及假設

  • 研究目的
  • 假設
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 各類藥物
    • 各給藥途徑
    • 各流通管道
    • 各地區
  • COM (Coherent Opportunity Map)

第3章 市場動態,法規及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 技術的進步
  • 流行病學
  • 產品回收
  • 政府的配合措施
  • 歷史概要
  • 合併和收購
  • 法規及償付方案
  • 波特的五力分析
  • PEST分析

第4章 全球氣喘治療藥市場:各類藥物

  • 簡介
  • 皮質類固醇
  • β2促效劑(長效型及短效型)
  • 白三烯抑制劑
  • 長效型毒蕈鹼拮抗劑(LAMA)
  • 白細胞介素拮抗劑
  • 抗免疫球蛋白E(IgE)劑
  • 組合產品(包含β2促效劑/皮質類固醇,β2促效劑/毒蕈鹼拮抗劑/皮質類固醇以及其他)
  • 其他

第5章 全球氣喘治療藥市場:各給藥途徑

  • 口服
  • 吸入
  • 注射

第6章 全球氣喘治療藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球氣喘治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • ASEAN
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他南美
  • 非洲
    • 北非
    • 中非
    • 南非
  • 中東
    • GCC各國
    • 以色列
    • 其他中東

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • GlaxoSmithKline Plc.
    • Philips Healthcare
    • AstraZeneca Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim GmbH
    • Sanofi- Aventis SA
    • CareFusion Corporation
    • Sunovion Pharmaceutical Ltd.
    • Merck & Co. Inc.
    • Roche Diagnostics
  • 分析師的意見

第9章 章節

  • 參考文獻
  • 調查方法
  • 本公司與銷售方面

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Asthma is a long-term inflammatory disease that causes inflammation and narrowing of the airways in the lung. It is characterized by various symptoms such as swelling or inflammation in the airways linings, coughing, shortness of breath, and tightness of chest. Asthma is classified into many different types including allergic asthma, non-allergic asthma, adult onset asthma, exercised induced asthma (that occurs with physical exertion), nocturnal asthma, and occupational asthma. Nocturnal is also known as the nighttime asthma. It is very serious type of asthma therefore, it needs a proper diagnosis and treatment.

Market Dynamics:

Increasing launches of nebulizer by key players is expected to propel global asthma therapeutics market growth. For instance, in October 2018, Koninklijke Philips N.V. announced launch of its new mesh nebulizer, InnoSpire Go, in North America. This is used for the treatment of respiratory diseases including asthma. It is portable, hand-held nebulizer system, which is short time treatment. It delivers the medicine in just four minutes. InnoSpire Go designed for both adults and children.

However, product recall is major restraining factor for asthma therapeutics market growth, which is expected to hamper the market growth. For instance, in August 2018, Camber Pharmaceuticals were issued product recall alert from U.S. Food and Drug Administration for its Montelukast Sodium Tablets. These tablets are recalled because Montelukast Sodium Tablet bottles contain wrong medicine (Losartan Potassium Tablet).

Key features of the study:

  • This report provides in-depth analysis of the global asthma therapeutics market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global asthma therapeutics market based on the following parameters-company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
    • Key players covered as a part of this study include, GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.
    • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
    • The global asthma therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for global asthma therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Asthma Therapeutics Market, By Drug Class:
    • Corticosteroids
    • Beta2-Agonists (Long-Acting and Short-Acting)
    • Leukotriene Inhibitors
    • Long-Acting Muscarinic Antagonists (LAMA)
    • Interleukin Antagonists
    • Anti-Immunoglobulin E (IgE) Agents
    • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
    • Others
  • Global Asthma Therapeutics By Route of Administration:
    • Oral
    • Inhalation
    • Injection
  • Global Asthma Therapeutics market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Asthma Therapeutics market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
    • By Drug Class
  • Corticosteroids
  • Beta2-Agonists (Long-Acting and Short-Acting)
  • Leukotriene Inhibitors
  • Long-Acting Muscarinic Antagonists (LAMA)
  • Interleukin Antagonists
  • Anti-Immunoglobulin E (IgE) Agents
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
  • Others
    • By Route of Administration:
  • Oral
  • Intravenous
  • Subcutaneous
    • By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • GlaxoSmithKline Plc.,*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Philips Healthcare
  • AstraZeneca Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim GmbH
  • Sanofi-Aventis SA
  • CareFusion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Roche Diagnostics.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Technology Advancements
  • Epidemiology
  • Product Recalls
  • Government Initiatives
  • Historical Overview
  • Merger and Acquisition
  • Regulatory and Reimbursement Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Asthma Therapeutics Market, By Drug Class, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Beta2-Agonists (Long-Acting and Short-Acting)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Leukotriene Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Long-Acting Muscarinic Antagonists (LAMA)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Interleukin Antagonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Anti-Immunoglobulin E (IgE) Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million

5. Global Asthma Therapeutics Market, By Route of Administration, 2018 - 2026, (US$ Million)

  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Inhalation
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million

6. Global Asthma Therapeutics Market, By Distribution Chanel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Asthma Therapeutics Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channels, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2026, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channels, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Philips Healthcare
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • AstraZeneca Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Sanofi- Aventis SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • CareFusion Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Sunovion Pharmaceutical Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Roche Diagnostics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top